Plot thickens as Lilly, J&J-backed Protagonist files for $75M IPO

Nasdaq tower

A year after the small, early-stage Californian IBD biotech Protagonist Therapeutics managed to raise $40 million, the company is now seeking to go public with a $75 million offering.

The Milpitas, CA-based biotech is doing early work on an oral peptide drug to treat inflammatory bowel disease (IBD), which includes major blockbuster conditions such as Crohn’s disease and ulcerative colitis.

Current treatments--such as the $13 billion a year Humira (adalimumab) from AbbVie ($ABBV)--are injectable. Protagonist, however, will hope to gain an edge by taking the oral route, a major next-gen hurdle that could pave the way to safer, more effective and easier-to-manage drugs.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

This is no easy task, as the digestive system is a very tricky route for oral peptides, but Protagonist’s early-stage work in the field on its Phase I candidate PTG-100 and preclinical work on PTG-200 have been enough to garner interest from the venture arms of Eli Lilly ($LLY) and Johnson & Johnson ($JNJ) for its $40 million round last year.

It will now hope this interest will grow for its $75 million offering, coming as it does during a particularly rough patch for biotech IPOs--although there has been a small lift in the market in recent months.

The biotech, which was founded in 2001 as a spinout from the University of Queensland's Institute of Molecular Biosciences, plans to list on the Nasdaq under the symbol "PTGX."

- check out the Renaissance Capital brief

Related Article:
Protagonist Therapeutics lands $40M round for an oral peptide IBD drug

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.